Supplemental Digital Content
Table 5. Cases of Treatment Failure (N=16) in the Entire Patient Cohort (N=437) Patient Age T-Category PSA Biopsy
Gleason Score
PSA nadir (ng/mL)
Time to Failure (months)
Site(s) of Failure
1 70 T2b 5.7 3+4 1.7 24.4 Local and distant (bone)
2 75 T2a 9.4 3+4 2.3 12.9 Distant (bone)
3 69 T1c 9.1 3+4 1 18.1 Distant (bone)
4 73 T2a 10.8 3+3 1.5 36.6 Nodal (pelvic LNs)
5 74 T2a 10.1 3+4 0.6 24.3 Distant (bone)
6 67 T1c 8.9 4+3 0.6 49.3 Distant (bone)
7 75 T1c 14.3 4+3 0.8 39.8 PSA only
8 81 T2b 3.7 3+4 0.3 40.5 Local
9 62 T1c 7.2 3+4 0.7 49.7 PSA only
10 73 T1c 8.2 3+4 1.3 9.6 Distant (bone)
11 78 T2b 2.9 4+3 0.3 41.1 PSA only
12 77 T1c 9.5 4+3 1.3 12.4 Nodal (pelvic LNs)
13 84 T2b 9.3 3+4 1.7 36.7 Nodal (para-aortic LNs)
14 74 T1c 8.3 4+3 1.2 25.3 Local
15 71 T1c 4.7 3+4 2.8 9.4 Distant (bone)
16 67 T1c 4.1 4+3 0.9 8.2 PSA only
Patients 1-14 underwent SBRT, while patients 15-16 underwent HDR-B. PSA=prostate-specific antigen;
SBRT=stereotactic body radiotherapy; HDR-B=high-dose-rate brachytherapy; LNs=lymph nodes
